Ergoloid
As of the edition of 20 October 2026, Ergoloid is a drug: marketed, first approved in 1968 (CA); acts on ADRA1A, ADRA1B and ADRA1D and 10 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Unknown
- Brand name
- Hydergine
- First approved
- 31 December 1968 (CA)
- Approvals on record
- 7 in 2 regions
- Holder of the most recent approval
- Novartis; 2 holders in all
- Registered trials
- 1, 0 stopped early
- Disease areas
- Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
13 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product13 company-target rows are on route B because of Ergoloid.
See the 13 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| HTR1A | 5-hydroxytryptamine receptor 1A | P08908 |
| ADRA2A | Alpha-2A adrenergic receptor | P08913 |
| DRD2 | Dopamine receptor D2 | P14416 |
| ADRA2B | Alpha-2B adrenergic receptor | P18089 |
| ADRA2C | Alpha-2C adrenergic receptor | P18825 |
| DRD1 | Dopamine receptor D1 | P21728 |
| DRD4 | Dopamine receptor D4 | P21917 |
| DRD5 | Dopamine receptor D5 | P21918 |
| ADRA1D | Alpha-1D adrenergic receptor | P25100 |
| HTR1B | 5-hydroxytryptamine receptor 1B | P28222 |
| ADRA1A | Alpha-1A adrenergic receptor | P35348 |
| ADRA1B | Alpha-1B adrenergic receptor | P35368 |
| DRD3 | Dopamine receptor D3 | P35462 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 1 |